Taiclone®
Quality Guarantee

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

RG7112

Catalog No: tcsc0330

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
939981-39-2

Formula:
$C_{38}H_{48}Cl_2N_4O_4S$

Pathway:
Apoptosis

Target:
MDM-2/p53

Purity / Grade:
>98%

Solubility:
H2O :

Alternative Names:
RO5045337

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
727.78

Product Description

RG7112 is the first clinical and orally available **MDM-2/p53** inhibitor designed to occupy the p53-binding pocket of MDM2, with the **K d** value of 11 nM.

IC50 & Target: Kd: 11 nM (MDM2)[1]

In Vitro: RG7112 (2.5μM) is more active against proliferation of liposarcoma cells, and especially those with wild-type p53. Treatment of cells with either Nutlin-3A or RG7112 induces cell-cycle arrest and apoptosis in the p53-WT cell line 93T449. RG7112 treatment reduces cell viability much more than Nutlin-3A in HT-1080, SW684, 93T449, and SW872 cells[1]. RG7112 shows potent antitumor activity against a panel of solid tumor cell lines. Treatment of cancer cells expressing wild-type p53 with RG7112 activates the p53 pathway, leading to cell-cycle arrest and apoptosis[2].

In Vivo: RG7112 is highly synergistic with androgen deprivation in LNCaP xenograft tumors. RG7112 (25-200 mg/kg, p.o.) to human xenograft-bearing mice at nontoxic concentrations causes dose-dependent changes in proliferation/apoptosis biomarkers as well as tumor inhibition and regression[2].